Full Press Release Details
Zymeworks’ Lead Asset, ZW25, Granted Fast Track Designation from the FDA.
ZYME
Zymeworks’ Lead Asset, ZW25, Granted Fast Track Designation from the FDA
Key Takeaway: Zymeworks’ Lead Asset, ZW25, Granted Fast Track Designation from the FDA
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers